Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

NCT03457896 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

NETWORK

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Trastuzumab
DRUG: Cetuximab
DRUG: Neratinib
DIAGNOSTIC_TEST: Guardant360 Diagnostic Test

Sponsor

NSABP Foundation Inc

Collaborators

[object Object]